Osmind’s Post

Did you know that between 2016 and 2021, Psychiatry (+26.3%) saw the second most growth in first-year ACGME fellows and residents? 💡 This growth is prominently due to lifestyle choices—in particular the ability to control one’s own calendar. As psychiatry grows, there has also been an increase in interest in telepsychiatry. This allows patients who do not have immediate access to mental health services (eg, those who live in rural communities) to receive care from trained psychiatric clinicians. Learn more: https://lnkd.in/gfxEWa4S #RuralGME #RuralHealth

The Rising Tide of Pharmacogenetics in Psychiatry: A Beacon of Hope for Depression Treatment In a world where mental health is increasingly gaining the attention it deserves, a new report throws light on a promising trend: the Pharmacogenetics Testing Market in Psychiatry, particularly for depression, is projected to soar with an impressive CAGR of 9.5% by 2029. This is not just a statistic; it's a testament to the burgeoning role of personalized medicine in transforming mental health care. Here's what this means for us in the healthcare sector: Tailored Treatments in Psychiatry: The growth in pharmacogenetics testing underscores a shift towards more individualized treatment plans in psychiatry. It's about finding the right medication for the right patient at the right time. Reducing the Trial-and-Error Approach: Traditional approaches to treating depression often involve a degree of guesswork. Pharmacogenetics promises a more informed, data-driven strategy, reducing the time and emotional cost of finding effective treatments. Empowering Patients and Clinicians: This growth empowers both patients and clinicians with better treatment decision-making tools, leading to potentially better outcomes and improved patient satisfaction. A Call for Continued Innovation: The projected growth is also a clarion call for continued research and innovation in the field of pharmacogenomics. It highlights the need for sustained investment and collaboration among scientists, clinicians, and industry leaders. As a fervent advocate for the integration of genetic insights in clinical practice, I'm thrilled to see this positive trend. The potential for pharmacogenetics in psychiatry, particularly in managing depression, is immense. It's about time we embraced these advancements and leveraged them to improve mental health outcomes. I invite my colleagues, researchers, and healthcare professionals to join the conversation. How do we further this momentum? What are the challenges and opportunities ahead? Let’s be part of this exciting journey toward a more personalized approach to mental health care. #Pharmacogenetics #Psychiatry #DepressionTreatment #PersonalizedMedicine #MentalHealthInnovation #InnovativeGXHealth #PGXSmartMeds+

Do you, as a psychiatric provider, face challenges with medication adherence in your adult patients diagnosed with schizophrenia? Check out my summer interview in Mental Health Weekly published by Wiley publishing company alongside my colleague Dr. Martha Sajatovic, M.D., professor of psychiatry and neurology at Case Western Reserve University School of Medicine! We discuss our recent research collaboration on a comprehensive patient-level meta-analysis evaluation, bringing together insights from two pivotal studies: the PRIDE and PROSIPAL studies. This combined analysis delved into the risk of relapse in adult patients with schizophrenia, focusing on varying durations of illness (0-3 years, >3-5 years, and >5 years). We compared the effectiveness of long-acting injectable (LAI) paliperidone palmitate (PP) versus oral antipsychotics (OAPs). 🔍 Key Findings: Our research highlights that LAI PP can potentially lower the need for hospitalizations and other intensive psychiatric services, which has significant implications for the healthcare system. By reducing the economic and social burdens on patients, families, and the broader community, LAI PP offers a promising alternative to traditional OAPs. 💡 Broader Implications: One of the standout benefits of LAI PP is its ability to overcome barriers to medication adherence. Unlike daily OAPs, LAI PP requires less frequent dosing, which is particularly advantageous for populations facing social and economic challenges. Improved adherence can lead to better patient outcomes, enhancing the overall quality of life for individuals with schizophrenia. As an early career psychiatric mental health nurse practitioner I'm grateful to have a seat at the table! Collaboration between nurse practitioners and psychiatrists in research and clinical practice enhances patient care, improves health outcomes, and fosters innovation in the healthcare system. Our combined efforts ensure that mental health care is comprehensive, patient-centered, and evidence-based. #psychiatry #neuroscience #longactinginjectables #collaboration

Join the forefront of innovation! The University of North Carolina at Chapel Hill Department of Psychiatry, led by Dr.Robert McClure, is embarking on a groundbreaking journey and inviting you to participate in a pioneering clinical trial exploring the potential of psilocybin for treating Treatment-Resistant Depression (TRD). What is the study for?  This study seeks to answer critical questions: Can psilocybin, with assisted therapy, truly alleviate depression symptoms? How enduring are these effects? How Can You Get Involved?  If you or someone you know might benefit, take the first step by visiting the link below to learn more and apply! https://lnkd.in/gPx2QhSb What's in Store for Participants?  ✅ Screening and preparation visits ✅ Psilocybin treatment sessions ✅ Follow-up sessions over a year ✅ Surveys to track symptom changes and gather feedback Why It Matters? Depression weighs heavily on individuals worldwide, and current treatments often come up short. Psilocybin offers hope, but we need these trials to understand its full potential. This kind of research greatly enhances consumer trust and helps correct misconceptions about psychedelic medicines. For those of us involved in the ceremonial space, it offers scientific backing that helps connect traditional practices with widespread acceptance. This support enables us to promote and use these potent therapeutic tools more responsibly, fostering broader understanding and recognition of their significant benefits. Know someone who might be interested? Share this post, and let's make a difference together. Questions? Reach out to PilotPAT_study@med.unc.edu. #MentalHealth #MattZemon  #Psychedelics #PsilocybinResearch #UNCPsychiatry #MentalHealthMatters

Choosing the right EHR for your practice is crucial, especially with the current shifts in the market! Carlene MacMillan, MD, breaks down the process in a recent blog: "How to Choose the Best EHR for your Psychiatry Practice" and outlines 5 essential questions you should be asking. This comprehensive guide offers a framework to navigate the overwhelming EHR landscape and find your perfect fit. From understanding your needs to asking the right questions during demos, Dr. MacMillan covers it all! Ready to streamline your practice and enhance patient care? Download the EHR Buyer Spreadsheet provided in the blog to stay organized throughout your search. Seize the opportunity to discover your ideal EHR match! https://lnkd.in/gXFtFtqN #EHR #Psychiatry #HealthTech #PracticeManagement

🎉Our study in #BMC Psychiatry emphasizes the critical importance of addressing OCD symptoms among healthcare workers, especially during turbulent times-COVID-19 Tailored interventions are needed to support their well-being as pioneers of public health. https://lnkd.in/g3QfTCnY

The Promising Landscape of Pharmacogenetics in Psychiatric Care: Illuminating a Path for Depression Treatment In our evolving world, where mental health rightfully claims its spotlight, a recent report unveils an encouraging trajectory: the Pharmacogenetics Testing Market in Psychiatry, specifically for depression, is set to ascend with a remarkable CAGR of 9.5% by 2029. This isn't merely a statistic; it signifies the expanding role of personalized medicine in reshaping mental healthcare. For us in the healthcare sector, here's the significance: 1. Tailored Treatments in Psychiatry: The surge in pharmacogenetics testing signifies a shift toward more personalized treatment plans in psychiatry. It's about pinpointing the precise medication for the right patient at the right moment. 2. Reducing the Trial-and-Error Approach: Conventional approaches to treating depression often involve a level of trial and error. Pharmacogenetics offers a more informed, data-driven strategy, diminishing the time and emotional toll of discovering effective treatments. 3. Empowering Patients and Clinicians: This growth empowers both patients and clinicians with enhanced treatment decision-making tools, potentially leading to better outcomes and increased patient satisfaction. 4. A Call for Continued Innovation: The anticipated growth serves as a rallying cry for ongoing research and innovation in the realm of pharmacogenomics. It underscores the necessity for sustained investment and collaboration among scientists, clinicians, and industry leaders. As a passionate advocate for integrating genetic insights into clinical practice, I am excited to witness this positive trend. The potential for pharmacogenetics in psychiatry, especially in addressing depression, is monumental. It's high time we embrace these advancements and leverage them to enhance mental health outcomes. I extend an invitation to my colleagues, researchers, and healthcare professionals to join the conversation. How can we propel this momentum further? What challenges and opportunities lie ahead? Let's actively engage in this exhilarating journey toward a more personalized approach to mental healthcare. #Pharmacogenetics #Psychiatry #DepressionTreatment #PersonalizedMedicine #MentalHealthInnovation #InnovativeGXHealth #PGXSmartMeds+

New Brain Food - 🚀Navigating Female-Specific Complexities in Psychiatry 🧠 Dive deep into the intricate world of female-specific complexities in Psychiatry! 🌟 After a few readings, clinicians will recognise the minimal attention given to female-specific facets in treatment, realising its pivotal importance in treating psychiatric conditions. The article covers: 👇 1.👩⚕️ Female Stress Response 2. 💥 Oestrogen & PTSD 3. 🧠 Effect of Hormones on the Brain 4. 🌟 Affective Disorders in Women 5. 💫 PCOS and Mental Health 6. 🌀 Gender Differences in Schizophrenia 7. 🌡️ Hyperprolactinaemia and Mental Health 8. 🧬 Sex Differences in Neurodevelopment 9. 💊 Female-Specific Psychopharmacology Read here 👉 https://lnkd.in/dHrkFk-P #StressResponse #WomensHealth #Oestrogen #PTSDAwareness #Psychiatry #HormonalInfluence #BrainHealth #MentalHealth #AffectiveDisorders #Neuroscience #PCOSAwareness #Schizophrenia #GenderDifferences #Hyperprolactinaemia #MentalHealthAwareness #Neurodevelopment #SexDifferences #Psychopharmacology #WomenHealth #Psychsceneacademy #Psychscenehub

The use of #ketamine proved to be effective in the management of a patient with Huntington disease and suicidal thoughts, according to a recently published study in the Journal of the Academy of Consultation-Liaison Psychiatry. Read more: https://brnw.ch/21wIy2p #MentalHealth #RareDisease

Innovation can happen anywhere.